66 results about "Acropustulosis" patented technology

The present invention relates to a cosmetic composition, advantageously an eco-biological cosmetic composition, comprising: - polyglutamic acid or a salt thereof; and - at least one peptide derivative represented by the general formula (I) in which: - R1 represents a hydrogen atom, an acyl radical or an acyloxy radical; and - R2 represents the side chain of an alpha-amino acid chosen from the group consisting of phenylalanine, glutamic acid, arginine, cysteine, methionine, histidine and tyrosine. The present invention also relates to the use of said cosmetic composition for combating skin redness and / or skin aging; to its use for preventing and / or combating cutaneous vascular hyperproliferation and / or cutaneous inflammation and / or rosacea; and to a method for selecting compounds suitable for preventing and / or combating these pathologies.

The present disclosure relates to the use of MrgprX2 antagonists in the treatment of inflammatory conditions, for example, skin inflammatory conditions. The present invention also relates to pharmaceutical compositions comprising a MrgprX2 antagonist and a pharmaceutically acceptable carrier for topical or oral administration.

This invention relates to the field of peptide technology, and more particularly to a cyclic tetrapeptide compound, its preparation method, and its applications. The peptide compound has the structure shown in Formula I, or its stereoisomer or salt thereof: c(AA1-AA2-AA3-AA4), Formula I. The cyclic tetrapeptide compound can simultaneously inhibit the release of the inflammatory factor IL-6 and effectively scavenge reactive oxygen species DPPH, ABTS, and PTIO. It can effectively inhibit the production of reactive oxygen species, alleviate skin inflammation, and improve skin condition, showing great promise in the fields of anti-inflammatory and antioxidant applications.

The present application provides a marine alga composition with soothing and repairing effects, which combines sea fennel extract and d. capillata extract, inhibits skin inflammation, promotes expression of skin protective proteins, solves skin inflammation, and has excellent soothing and moisturizing and repairing effects, fundamentally solves a series of problems of the skin, has high and efficient effects, and has a good application prospect.

The invention relates to the field of medicines, in particular to a stem cell factor composite medicine composition for treating allergic dermatitis and a preparation method thereof. The composite pharmaceutical composition is prepared from the following raw materials in parts by weight: 5 to 10 parts of stem cell factors, 2 to 6 parts of agilawood extract, 1 to 3 parts of forskolin and 0.1 to 0.3 part of stabilizer. The pharmaceutical composition can effectively inhibit bacteria, relieve pain and relieve itching, and can remarkably relieve itching and inflammation caused by allergic dermatitis by inhibiting release of inflammatory factors.

The application discloses a kind of self-assembly hydrogel, preparation method and application, belong to material field.The application claims to protect a kind of self-assembly hydrogel, it is formed by glycyrrhizic acid, five gallate glucose and paeonol by molecular self-assembly;Wherein, the mass ratio of glycyrrhizic acid and five gallate glucose, paeonol is (10~60) :(1~8) :(2~8).The self-assembly hydrogel provided by the application is suitable for skin, raw material is natural, biocompatibility is good, mechanical and storage stability is excellent, can release paeonol and the transdermal effect is good, three components synergistically improve atopic dermatitis and other skin inflammation, and clinical value is high.In addition, the preparation process of the self-assembly hydrogel of the application is simple, can be prepared using conventional one-pot method, easy to produce.Therefore, the self-assembly hydrogel of the application has the prospect of developing into paeonol sustained-release delivery system, paeonol transdermal sustained-release preparation or skin inflammation treatment drug.

The invention discloses a bacteriostatic and anti-inflammatory polypeptide extract and application thereof in a Yao bath. The polypeptide extract is extracted from rhizomes of Coptis chinensis (Coptis chinensis Franch.), and is obtained through extraction with a phosphate buffer solution, ultrafiltration and gel chromatography purification, and the polypeptide is as shown in SEQ ID No: 1. Experiments show that the polypeptide extract has significant bacteriostatic activity on pathogenic bacteria such as escherichia coli, shows a dose-dependent anti-inflammatory effect in an RAW264.7 cell model, can effectively inhibit NO release, and has a cell survival rate of 92% or more and excellent biological safety. The polypeptide extract is applied to a Yao bath preparation, O / W type emulsion is prepared, 10 volunteers try on the Yao bath preparation, the improvement rate on mild skin inflammation symptoms (such as red and swollen and pruritus) reaches 87%, and anaphylactic reaction is avoided. The polypeptide extract is simple in preparation process and high in activity, and has a wide application prospect in the fields of cosmetics and medicines.

The invention provides a polianthes tuberosa corm extract and a preparation method and application thereof.The preparation method includes the steps that fresh polianthes tuberosa corm and water are mixed and then smashed, then stirring extraction is conducted at the temperature of 50-70 DEG C, supernate is collected through centrifugation and filtered, and polyhydric alcohol with the volume concentration of 30-50% is added; and the polyol is 1, 3-butanediol or glycerol. According to the tuberose corm extract disclosed by the invention, by inhibiting TNF-alpha induced cortisol excessive secretion and promoting beta-ennorphin release, the dual effects of inhibiting stress and promoting soothing are realized, and the problems of skin inflammation, sensitivity, barrier damage and the like caused by psychological emotion stress are solved.

The invention relates a pharmaceutical composition comprising from 0.001 to 2% (w / v) of propane-1,2-diol as the only anti-inflammatory agent and at least one bioadhesive polymer. The pharmaceutical composition can be used in amelioration, prevention or treatment of an inflammatory condition in a mucous membrane or skin of a subject, and / or in treatment of pain associated with such an inflammatory condition.

The application relates to a stoma base plate which is characterized in that the stoma base plate comprises a fitting layer, the middle of the fitting layer is provided with a through hole matched with the size of a stoma, the inner surface of the fitting layer is provided with textures, and the rigidity of the fitting layer is distributed in a gradient decreasing mode from the edge of the stoma to the peripheral direction; the rigidity of the contact part of the fitting layer and the concave area on the skin surface is lower than that of the adjacent flat area around the fitting layer, and the rigidity of the edge of the fitting layer is higher than that of the adjacent flat area around the fitting layer; and a buffer layer having a porous structure. According to the application, through the collaborative design of the stiffness gradient of the fitting layer, softening of the local concave area and edge hardening, the fitting layer can accurately adapt to the unique abdomen curved surface and skin microtopography of a patient, when the patient breathes and moves, dynamic deformation matching can be achieved through the design, the problem of excrement leakage caused by static non-fitting and dynamic gaps is solved, and the application range is widened. Complications such as skin inflammation, infection and the like caused by the traditional Chinese medicine composition are fundamentally prevented.

This invention belongs to the field of biomedical technology, specifically relating to the application of SMOC2 protein in the preparation of psoriasis treatment drugs. The amino acid sequence of the SMOC2 protein is shown in SEQ ID NO.1. This invention has discovered that SMOC2 protein can treat psoriasis, and therefore provides the application of SMOC2 protein in the preparation of psoriasis treatment drugs. Using SMOC2 protein can treat or improve the scaling, erythema, and thickening phenotypes of the skin, as well as inhibit the abnormal proliferation of keratinocytes and the expression of inflammatory factors IL1β, IL23, cAMP, TNFα, CXCL2, CXCL3, S100A8, and S100A9. By inhibiting the infiltration of neutrophils in inflammatory cells in psoriatic lesions, it exerts a therapeutic or alleviating effect on inflammatory skin diseases.

The invention relates to application of cembratrienediol in preparation of a medicine for preventing and treating rosacea, and belongs to the technical field of biological medicine. The invention provides an application of cembratrienediol in preparation of a medicine for preventing / or treating rosacea. The cembratrienediol can obviously improve erythema and inflammation of an injection area of a rosacea mouse model for a long time and a short time; the skin tissue pathological inflammation of the rosacea mouse model can be obviously relieved (including the thickening of the skin epidermis of the rosacea mouse model, the inflammatory cell infiltration of the skin tissue of the rosacea mouse model and the capillary hyperplasia of the skin tissue of the rosacea mouse model); skin inflammation of a rosacea patient can be remarkably relieved (including relieving pain of the skin of the rosacea patient and relieving the red and swollen degree of the skin of the rosacea patient), and skin injuries of the rosacea patient can be remarkably improved (including improving papules and pustules of the skin of the rosacea patient).

The invention discloses application of an Aldicanol compound in preparation of a medicine for treating chronic skin inflammation, and belongs to the technical field of medicines. In order to solve the problem that a method for effectively treating chronic scytitis lacks in the prior art, the invention provides an application of an Aldicanol compound in preparation of a medicine for treating chronic scytitis, the Aldicanol compound is extracted from dryopteris fragrans glandular hair, and the Aldicanol compound has the effects of remarkably improving skin erythema caused by chronic scytitis, reducing scales, improving the curative effect of chronic scytitis, improving the curative effect of chronic scytitis and the like. The spleen index is reduced; the skin epidermis thickness caused by chronic skin inflammation is obviously reduced, inflammatory cell infiltration is reduced, and hair follicle inflammation is obviously weakened; proinflammatory factors can be effectively inhibited, and expression of anti-inflammatory factors can be effectively promoted; the Aldicanol compound can be applied to the treatment of chronic skin inflammation.

A method for reducing the appearance of fine lines or wrinkles, treating skin inflammation, or reducing the appearance of reddened or erythemic skin is disclosed. The method can include applying to skin having a fine line or wrinkle, having inflammation, or having a reddened or erythymic appearance a composition that includes tetrahexyldecyl ascorbate and Acmella oleracea extract, wherein application of the composition to the skin reduces the appearance of the fine line or wrinkle, treats skin inflammation, or reduces the appearance of the reddened or erythemic skin.

The invention relates to application of pholidota chinensis exosome-like nano-vesicles in preparation of a product with a skin care function, and belongs to the technical field of plant biology. The pholidota chinensis exosome-like nano-vesicle is rich in bioactive substances, has excellent biocompatibility and transmembrane delivery potential due to the bimolecular phospholipid layer structure, and has various skin care effects. Tests show that the compound has no toxicity to RBL-2H3 and RAW264.7 cells within the concentration of 6.25-100 [mu] g / mL, has remarkable proliferation promoting capacity to HaCaT cells within the concentration of 50-100 [mu] g / mL, and meets the safety requirements of cosmetics. In addition, the vesicles can effectively remove ABTS < + > and DPPH free radicals, the inhibiting capacity of the vesicles on DPPH is remarkably higher than that of aqueous extracts and close to that of VC, and the vesicles show an excellent antioxidant effect. Meanwhile, NO generation can be remarkably inhibited, and the effect of resisting skin inflammation is achieved.

The invention discloses an anti-inflammatory and anti-aging face cream and a preparation method thereof, and belongs to the technical field of cosmetics. The face cream disclosed by the invention is prepared from the following components in percentage by weight: 5.0 to 20.0 percent of broccoli fermentation filtrate, 0.05 to 0.2 percent of andrographolide encapsulated by nano-liposome, 0.5 to 5.0 percent of a skin barrier repairing agent and a matrix. Sulforaphane (greater than or equal to 400 mg / kg) in broccoli is enriched through a lactic acid bacteria fermentation technology, and the stability and the smell of the broccoli are improved; the problem that andrographolide is difficult to dissolve and easy to crystallize is solved through embedding of nano-liposome (the particle size is 40-80 nm, and the encapsulation efficiency is larger than or equal to 85%), and the transdermal property of andrographolide is improved. The two are combined to synergistically activate an Nrf2 antioxidant pathway and inhibit an NF-kappa B inflammation pathway, and the two pathways intervene in inflammatory aging. Human body tests show that after the face cream is used for 4 weeks, the depth of wrinkles can be remarkably reduced (28.6%), the level of skin inflammatory factors TNF-alpha can be reduced (50.4%), and the face cream is free of any irritating reaction, has an excellent anti-aging effect and extremely high safety and is particularly suitable for sensitive skin.

The application belongs to the technical field of medicine application, and relates to application of fluparoxane in preparation of medicines for treating skin inflammation and inhibiting TRPV3 channels. On one hand, a new use of fluparoxane medicines is developed, and fluparoxane can be used for treating skin inflammation. Fluparoxane also has good TRPV3 inhibiting activity, and can be used for preparing medicines for treating diseases related to enhanced TRPV3 ion channel activity. On the other hand, a new way for treating skin inflammation is provided. Therefore, the new use of fluparoxane provided by the application has great value for scientific research and clinical research.

The present application relates to traditional Chinese medicine composition and its application in the field of skin inflammation diseases, and discloses a kind of drug composition for treating skin inflammation and its preparation method and application.The composition is prepared from white fungus, tribulus terrestris, smilax glabra, kochia scoparia, honeysuckle, baishiy, rehmannia glutinosa, oak, peony, radix lithospermi, periostracum cicadae, licorice, gardenia and sophora flavescens.The UPLC-Q-TOF-MS identification contains 110 kinds of components;Animal experiments show that it can significantly reduce psoriasis skin lesions, down-regulate TNF-alpha, IL-1beta and IL-6, up-regulate IL-10, and inhibit PI3K-Akt pathway.The present application has clear components, clear mechanism and definite curative effect, and can be used for preparing medicine for treating psoriasis, chronic urticaria and senile pruritus.

The application discloses a synergistic ganoderma lucidum fermentation extract composition and application thereof in skin antioxidation, immunoregulation, anti-aging and anti-wrinkle skin tendering. The composition provided by the application contains the following raw materials in percentage by weight: 0.1-10% of ganoderma lucidum fermentation extract, 0.01-10% of magnesium ascorbyl phosphate, 0.01-5% of glycyrrhiza extract, 0.1-5% of tocopherol, 0.05-3% of boswellic acid extract, 0.01-3% of asiaticoside, 0.01-0.5% of coffee acid, and the balance of solvent. The composition provided by the application realizes three-effect synergism of "immune homeostasis-antioxidation repair-antioxidation" through specific component cooperation, can significantly improve skin inflammation, stabilize the skin immune microenvironment, delay skin aging, and has important application value in the development of skin antioxidation, immunoregulation, anti-aging and anti-wrinkle skin tendering products.

The present application relates to the technical field of Mongolian medicine external preparation, in particular to a Mongolian medicine Sendeng-4 cream. The cream is prepared from Sendeng, Terminalia chebula, Gardenia jasminoides and Chinese Hopea as raw materials, and effective components are enriched by composite enzymolysis, supercritical CO2 two-phase extraction, gradient membrane separation and molecular imprinting purification. Then, the cream is prepared by adding composite penetration enhancer and plant source preservative after the pH-ROS response carrier targets drug loading and the temperature-sensitive composite matrix is microfluidic adapted. The present application solves the defects of traditional preparation, such as insufficient dissolution, poor stability and weak targeting, and has high cream purity, good skin permeability, excellent safety, stable long-term storage performance, and is suitable for skin inflammation, eczema, itching and other diseases. The cream has the advantages of traditional Mongolian medicine and modern preparation, and has a wide clinical application prospect.

This invention provides an acne-removing gel candy and its preparation method. The raw materials for preparing the acne-removing gel candy include anti-inflammatory substances, antioxidants, skin improvers, acne bacteria inhibitors, and gel fillers. The anti-inflammatory substances include Haematococcus pluvialis oil, vitamin C derivatives, and plant oils; the antioxidants include yeast extract. This invention inhibits acne formation through anti-inflammatory substances, alleviates the effects of skin inflammation on the dermis to accelerate acne elimination through antioxidants, improves skin properties through skin improvers, and inhibits the proliferation of acne bacteria to repair acne. This multi-faceted approach effectively inhibits acne formation, clears acne, and improves skin after acne treatment.

The invention discloses application of a ganoderma lucidum extract in preparation of a product for improving skin problems, bidirectional regulation of skin homeostasis is realized through a dual-action mechanism, on one hand, conversion of corticosterone to cortisol is inhibited, and on the other hand, the skin homeostasis is inhibited; the problems of skin barrier injury, skin basement membrane injury, excessive sebum secretion, accelerated aging and the like caused by excessive cortisol are relieved; on the other hand, by inhibiting differentiation of macrophages induced by noradrenaline to inflammation phenotypes, the cortisol level is reduced, meanwhile, the skin inflammation response excited by early pressure is effectively controlled, and bidirectional regulation of skin homeostasis is achieved.

The invention discloses lactobacillus reuteri CCFM1502 capable of up-regulating skin ceramide synthesis and reducing skin inflammation and a metagen of the lactobacillus reuteri CCFM1502, and belongs to the technical field of microorganisms and medicines. The lactobacillus reuteri CCFM1502 provided by the invention can remarkably promote synthesis of ceramide when being externally used and orally taken, and can reduce skin inflammation response of mice after being orally taken. Specifically, the strain lysate and the fermentation supernatant both can promote HaCaT cells to secrete ceramide; the total amount of ceramide in skin can be up-regulated by oral administration of viable bacteria and metabiotics of the lactobacillus reuteri, apparent indexes of the skin can be regulated and controlled, inflammatory reactions in vivo and tissues can be reduced, and particularly, the effect of fermentation supernate of the lactobacillus reuteri is optimal. And the thallus components and viable bacteria have obvious effects in promoting the expression of anti-inflammatory factors in skin tissues. Therefore, the lactobacillus reuteri has a huge application prospect in preparation of a product for promoting synthesis of the natural active ingredient ceramide of the skin.

This application provides the use of an antimicrobial peptide in the preparation of skin care products. The antimicrobial peptide of this application can effectively inhibit *Propionibacterium acnes* and *Malassezia*, thereby preventing skin problems such as acne, skin inflammation, and dandruff caused by the overgrowth of these two bacteria. Therefore, the antimicrobial peptide of this application has skin care uses in inhibiting acne, relieving skin inflammation such as folliculitis, pityriasis versicolor, and seborrheic dermatitis, and in inhibiting dandruff, and has significant practical value.

The application provides a composition for regulating intestinal flora to intervene in rose acne, comprising oral preparations and skin external preparations thereof, and relates to the technical field of biological medicines.The composition is composed of a prebiotic component inulin or a dandelion water extract containing inulin, and a humanized rhamnosus strain or a bacterial body lysate, culture supernatant or metabolite thereof.The composition can promote the proliferation of the humanized rhamnosus in the intestinal tract after being taken orally, significantly enhance the tryptophan metabolism capacity of the humanized rhamnosus, and improve the intestinal indole-3-lactic acid level;ILA enters blood through the intestinal-skin axis, and acts on the skin keratinocyte aromatic receptor, so that the immune homeostasis is systematically regulated and the skin inflammation is relieved.Experiments prove that the composition has a significant prevention and intervention effect on a rose acne model of mice induced by LL-37, can reduce the erythema area, and relieve the inflammatory symptoms.

This invention relates to a lactobacillus composition for alleviating atopic dermatitis. This lactobacillus composition comprises at least one of *Lactobacillus johnsonii* strain GKJ2 and *Lactobacillus plantarum* strain GKK1. When administered to subjects suffering from atopic dermatitis for a continuous period, it can regulate Th1, Th2, Treg, and Th17 cellular immunity, alter the intestinal flora, and increase the concentration of short-chain fatty acids in the intestine, thereby alleviating atopic dermatitis. Therefore, this lactobacillus composition can be used as an active ingredient in the preparation of various compositions for alleviating atopic dermatitis.

Disclosed herein are topical compositions comprising Centella asiatica (Centella asiatica) extract and mandelic acid, wherein the composition has a pH of less than 5, and methods of using the compositions to reduce cellular senescence in the skin and treat dermatoporosis. The topical composition comprising Centella asiatica extract and mandelic acid is effective in reducing the number of senescent cells in mammalian dermis, reducing the senescence-associated secretory phenotype (SASP), downregulating at least one SASP-related gene, increasing the expression of at least one cell cycle-related gene in dermal fibroblasts, downregulating at least one gene associated with skin inflammation, and increasing fibroblast turnover.

This invention provides a method for preparing natural nanophases of a Uyghur medicine compound preparation for treating eczema and its application. Based on a patent (CN201911308259.1) for a compound preparation for treating skin inflammation, this method regulates the solvent composition, concentration conditions, and mixing method of the extraction system to form a stable multiphase structure. Further, differential centrifugation is used to achieve directional separation of phases with different particle sizes, thereby obtaining natural nanophases. The obtained natural nanophases enrich the active ingredients in the compound preparation, significantly reduce cytotoxicity, and enhance biocompatibility. Simultaneously, they significantly inhibit NO production and exhibit eczema-related antibacterial activity, improving drug absorption and utilization efficiency, thus demonstrating superior eczema-related biological activity. This method also addresses the issue of the darker color of the product obtained from the original preparation process, improving the acceptability of the preparation and medication adherence.

The application relates to application of cedrene diol in preparation of medicines for preventing and treating rosacea, and belongs to the technical field of biological medicines. The application provides application of cedrene diol in preparation of medicines for preventing and / or treating rosacea. The cedrene diol can significantly improve redness and inflammation of an injection area of a rosacea mouse model in long and short terms, can significantly relieve skin histopathological inflammation of the rosacea mouse model (including improving thickening of skin epidermis of the rosacea mouse model, reducing inflammatory cell infiltration of skin tissue of the rosacea mouse model, and reducing capillary proliferation of skin tissue of the rosacea mouse model), can significantly reduce skin inflammation of a rosacea patient (including reducing pain of the skin of the rosacea patient and relieving redness of the skin of the rosacea patient), and can significantly improve skin damage of the rosacea patient (including improving papules and pustules of the skin of the rosacea patient).

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic / injured area).